NEWS

Arbutus licenses LNP delivery technology to Alexion

Friday, Mar 17, 2017

Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate. Arbutus Biopharma Corp says under terms of license agreement, Alexion will pay Arbutus $7.5 million upfront.

Arbutus Biopharma Corp says Alexion will also make payments of up to $75 million for achievement of development, regulatory, and commercial milestones.

Arbutus Biopharma Corp says transaction enables Alexion to address delivery for therapeutic application of messenger RNA.

Arbutus Biopharma Corp says transaction also enables Alexion to rapidly enter clinical development with its MRNA product candidate.

Arbutus Biopharma - licensed to Alexion Pharma its proprietary lipid nanoparticle technology for exclusive use in one of Alexion's rare disease programs.

 

Source: reuters.com

Other News